Eiger BioPharmaceuticals to Participate in U.S. and International Investor and Partnership Conferences in March
- China Healthcare Investment & Partnering Symposium (CHIPS),
March 15-17, 2018 at theIntercontinental Hotel inHangzhou, China .
Eiger will present and host one-on-one meetings. - Oppenheimer 28th Annual Healthcare Conference, Presentation
March 20, 2018 ,3:20 pm ET at TheWestin New York Grand Central inNew York City .
Eiger will host one-on-one meetings. China Healthcare Investment Conference (CHIC),March 27-29, 2018 atRitz-Carlton Shanghai Pudong Hotel inShanghai, China .
Eiger will present and host one-on-one meetings.
A live webcast of the Oppenheimer presentation will be available on the
About Eiger
Eiger is a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases. We are committed to translational innovation and the development of well-characterized drugs acting on newly identified or novel targets. Our mission is to systematically reduce the time and cost of the drug development process to more rapidly deliver important medicines to patients with rare diseases. Our lead program in Hepatitis Delta Virus (HDV) infection, is moving into Phase 3 with a single, pivotal trial planned to initiate by the end of the year. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
Note Regarding Forward-Looking Statements
This press release contains "forward-looking" statements that involve substantial risks and uncertainties.All statements other than statements of historical facts, including statements regarding our future financial condition, timing for and outcomes of clinical results, business strategy and plans and objectives for future operations, are forward looking statements. These forward-looking statements include terminology such as "believe," "will," "may," "estimate," "continue," "anticipate," "contemplate," "intend," "target," "project," "should," "plan," "expect," "predict," "could," "potentially" or the negative of these terms. Forward looking statements are our current statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ongoing and planned clinical development, the timing of and our ability to initiate or enroll clinical trials, and our ability to make regulatory filings and obtain and maintain regulatory approvals for lonafarnib, ubenimex, PEG IFN lambda, exendin 9-39 and our other product candidates, our intellectual property position, the potential safety, efficacy, reimbursement, convenience clinical and pharmaco-economic benefits of our product candidates, commercial opportunities, including potential market sizes and segments, our ability to commercialize, expectations regarding clinical trial data and
Various important factors could cause actual results or events to differ materially from the forward-looking statements that Eiger makes, including the risks described in the "Risk Factors" sections in the Quarterly Report on Form 10-Q for the quarter ended
Investors:
Email: [email protected]
Phone: 1-650-619-6115
View original content with multimedia:http://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-participate-in-us-and-international-investor-and-partnership-conferences-in-march-300608666.html
SOURCE